Sarepta Therapeutics has secured a platform technology designation from the FDA, signaling a regulatory shift to accelerate review processes for gene therapy applications targeting rare diseases. This status will facilitate faster approval of Sarepta's upcoming therapies built on their RNA editing platform, aligning with the FDA's efforts to promote innovation and address unmet medical needs in precision medicine.